We are pleased to announce that SYMATESE is entering a new phase of international growth. Building on 27 years of innovation, SYMATESE is aiming to double its revenue by 2028, targeting a global market valued at over €6 billion.
Key highlights include:
- Launch of our range of HA based injectables EVOLYSSE™, in the United States from April 2025, with rapid rollouts in Europe, China, and Brazil to follow with ESTYME®
- Strategic partnerships with leading global players such as L’ORÉAL, Galderma, Evolus, Nordic Pharma, and Zimmer.
- A new state-of-the-art production facility in Vourles (Lyon, France) to support rising demand, operational by 2027.
- A strong focus on innovation with our new COLD-X TECHNOLOGY® in the production of our HA based injectables, but also with NEVELIA®, a dermal regeneration matrix, a new range of breast implants from the PRYME® TECHNOLOGY by SYMATESE and LACRIFILL® for dry eye, and high safety and ethical standards.
This expansion marks a turning point for SYMATESE, as it shifts from product development to large-scale commercial growth, reaffirming its leadership in regenerative and aesthetic medicine.
Read the full press release here.
